Literature DB >> 22559757

Update of the Dutch Manual for Costing in Economic Evaluations.

Siok Swan Tan1, Clazien A M Bouwmans, Frans F H Rutten, Leona Hakkaart-van Roijen.   

Abstract

OBJECTIVES: In 2000, the first "Dutch Manual for Costing: METHODS and Reference Prices for Economic Evaluations in Healthcare" was published, followed by an updated version in 2004. The purpose of the Manual is to facilitate the implementation and assessment of costing studies in economic evaluations. New developments necessitated the publication of a thoroughly updated version of the Manual in 2010. The present study aims to describe the main changes of the 2010 Manual compared with earlier editions of the Manual.
METHODS: New and updated topics of the Manual were identified. The recommendations of the Manual were compared with the health economic guidelines of other countries, eliciting strengths and limitations of alternative methods.
RESULTS: New topics in the Manual concern medical costs in life-years gained, the database of the Diagnosis Treatment Combination (DBC) casemix System, reference prices for the mental healthcare sector and the costs borne by informal care-givers. Updated topics relate to the friction cost method, discounting future effects and options for transferring cost results from international studies to the Dutch situation.
CONCLUSIONS: The Action Plan is quite similar to many health economic guidelines in healthcare. However, the recommendations on particular aspects may differ between national guidelines in some respects. Although the Manual may serve as an example to countries intending to develop a manual of this kind, it should always be kept in mind that preferred methods predominantly depend on a country's specific context.

Mesh:

Year:  2012        PMID: 22559757     DOI: 10.1017/S0266462312000062

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  75 in total

Review 1.  Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries.

Authors:  Emelie Heintz; Andreas Gerber-Grote; Salah Ghabri; Francoise F Hamers; Valentina Prevolnik Rupel; Renata Slabe-Erker; Thomas Davidson
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  Hospital costs of ischemic stroke and TIA in the Netherlands.

Authors:  Leander R Buisman; Siok Swan Tan; Paul J Nederkoorn; Peter J Koudstaal; William K Redekop
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

3.  Treatment Outcome, Duration, and Costs: A Comparison of Performance Indicators Using Data from Eight Mental Health Care Providers in The Netherlands.

Authors:  E de Beurs; E H Warmerdam; S C C Oudejans; M Spits; P Dingemanse; S D D de Graaf; I W de Groot; H Houben; W G E Kuyck; E O Noorthoorn; M A Nugter; S C C Robbers; G E van Son
Journal:  Adm Policy Ment Health       Date:  2018-03

4.  Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?

Authors:  Peter Makai; Willemijn Looman; Eddy Adang; René Melis; Elly Stolk; Isabelle Fabbricotti
Journal:  Eur J Health Econ       Date:  2014-04-24

5.  Employer survey to estimate the productivity friction period.

Authors:  Kathleen Manipis; Stephen Goodall; Paul Hanly; Rosalie Viney; Alison Pearce
Journal:  Eur J Health Econ       Date:  2021-01-02

6.  A low fixed dose of prothrombin complex concentrate is cost effective in emergency reversal of vitamin K antagonists.

Authors:  Nakisa Khorsand; Lisette Giepmans; Karina Meijer; Reinier M van Hest; Nic J G M Veeger
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

Review 7.  Emergent Challenges in Determining Costs for Economic Evaluations.

Authors:  Josephine C Jacobs; Paul G Barnett
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

8.  ¹⁸F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study.

Authors:  H Balink; S S Tan; N J G M Veeger; F Holleman; B L F van Eck-Smit; R J Bennink; H J Verberne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-06       Impact factor: 9.236

9.  Treatment costs of acute myocardial infarction in the Netherlands.

Authors:  R R Soekhlal; L T Burgers; W K Redekop; S S Tan
Journal:  Neth Heart J       Date:  2013-05       Impact factor: 2.380

10.  Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

Authors:  Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.